79558-09-1
基本信息
100877
L 1q5041
L-165,041
COMPOUND P
L-165041, >=98%
L165041
L 165041
L-165,041 - CAS 79558-09-1 - Calbiochem
2-[4-[3-(4-acetyl-3-hydroxy-2-propylphenoxy)propoxy]phenoxy]-
4-[3-(4-ACETYL-3-HYDROXY-2-PROPYLPHENOXY)PROPOXY]PHENOXYACETIC ACID
物理化学性质
| 熔点 | 127-128 °C(lit.) |
| 熔点 | 127-128 °C(lit.) |
| 沸点 | 600.8±55.0 °C(Predicted) |
| 密度 | 1.222±0.06 g/cm3(Predicted) |
| 储存条件 | 2-8°C |
| 溶解度 | DMSO: >10 mg/mL |
| 溶解度 | 二甲基亚砜：>10 mg/mL |
| 酸度系数(pKa) | 3.23±0.10(Predicted) |
| 形态 | solid |
| 颜色 | off-white |
| 稳定性 | 感光 |
| InChI | 1S/C22H26O7/c1-3-5-19-20(11-10-18(15(2)23)22(19)26)28-13-4-12-27-16-6-8-17(9-7-16)29-14-21(24)25/h6-11,26H,3-5,12-14H2,1-2H3,(H,24,25) |
| InChIKey | HBBVCKCCQCQCTJ-UHFFFAOYSA-N |
| SMILES | CCCc1c(O)c(ccc1OCCCOc2ccc(OCC(O)=O)cc2)C(C)=O |
安全数据
| 危险性符号(GHS) |  GHS07 |
| 警示词 | 警告 |
| 危险性描述 | H302-H315-H319-H335 |
| 防范说明 | P261-P280-P301+P312-P302+P352-P305+P351+P338 |
| WGK Germany | 3 |
| WGK Germany | 3 |
| 存储类别 | 11 - Combustible Solids |
L-165041价格(试剂级)
| 报价日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
| 2026/06/05 | HY-20019R | L-165041 L-165041 (Standard) | 79558-09-1 | 5 mg | 1250元 |
| 2026/06/05 | HY-20019R | L-165041 L-165041 (Standard) | 79558-09-1 | 10 mg | 1910元 |
| 2026/06/05 | HY-20019R | L-165041 L-165041 (Standard) | 79558-09-1 | 25 mg | 3820元 |
常见问题列表
|
PPARδ 6 nM (Ki) |
PPARγ 730 nM (Ki) |
L-165041 is a PPARδ agonist, with K i s of 6 nM and appr 730 nM for PPARδ and PPARγ, respectively. L-165041 (1 or 5 µM) inhibits VEGF-induced endothelial cells (ECs) proliferation and migration. L-165041 negatively affects cell cycle progression in VEGF-activated human umbilical vein ECs (HUVECs). L-165041 (10 µM)inhibits PPARδ-independent, VEGF-induced angiogenesis. PPARδ ligand L-165041 inhibits PDGF-induced rVSMC proliferation and migration. With 1 h of L-165041 pretreatment, PDGF-induced cellular migration is inhibited. L-165041 (10 μM) significantly suppresses S phase transition induced by PDGF.
L-165041 (5 mg/kg/day, i.p.) significantly lowers the formation of lipid droplets in mice. L-165041 markedly reduces the level of both the hepatic cholesterol and triglycerides in mice. L-165041 increases mRNA expression levels of PPARδ compared to the vehicle group. Lipoprotein lipase (LPL) expression in L-165041-treated mice is significantly higher than that in the vehicle group.